PL2928870T3 - Ligandy receptora neurotensyny - Google Patents

Ligandy receptora neurotensyny

Info

Publication number
PL2928870T3
PL2928870T3 PL13814827T PL13814827T PL2928870T3 PL 2928870 T3 PL2928870 T3 PL 2928870T3 PL 13814827 T PL13814827 T PL 13814827T PL 13814827 T PL13814827 T PL 13814827T PL 2928870 T3 PL2928870 T3 PL 2928870T3
Authority
PL
Poland
Prior art keywords
ligandy
neurotensin receptor
neurotensin
receptor
Prior art date
Application number
PL13814827T
Other languages
English (en)
Polish (pl)
Inventor
Frank Osterkamp
Christiane Smerling
Ulrich Reineke
Christian Haase
Jan Ungewiß
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of PL2928870T3 publication Critical patent/PL2928870T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL13814827T 2012-12-07 2013-12-06 Ligandy receptora neurotensyny PL2928870T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands
EP13814827.5A EP2928870B1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (1)

Publication Number Publication Date
PL2928870T3 true PL2928870T3 (pl) 2020-09-21

Family

ID=47355771

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13814827T PL2928870T3 (pl) 2012-12-07 2013-12-06 Ligandy receptora neurotensyny
PL20166422.4T PL3712131T3 (pl) 2012-12-07 2013-12-06 Ligandy receptora neurotensyny

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20166422.4T PL3712131T3 (pl) 2012-12-07 2013-12-06 Ligandy receptora neurotensyny

Country Status (20)

Country Link
US (3) US10961199B2 (https=)
EP (3) EP2740726A1 (https=)
JP (2) JP6576828B2 (https=)
KR (1) KR102290803B1 (https=)
CN (2) CN109320502B (https=)
AU (1) AU2013354422B2 (https=)
BR (1) BR112015012530B1 (https=)
CA (1) CA2893605C (https=)
DK (2) DK3712131T3 (https=)
ES (2) ES2941629T3 (https=)
FI (1) FI3712131T3 (https=)
HU (2) HUE050388T2 (https=)
IL (1) IL239080B (https=)
MX (1) MX370354B (https=)
PL (2) PL2928870T3 (https=)
PT (2) PT2928870T (https=)
RU (1) RU2671970C2 (https=)
SG (2) SG11201503880YA (https=)
WO (1) WO2014086499A1 (https=)
ZA (1) ZA201503446B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
SI3380495T1 (sl) 2015-11-24 2022-01-31 Transfert Plus, S.E.C. Peptidne spojine in peptidni konjugati za zdravljenje raka z receptorsko posredovano kemoterapijo
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
JP7773990B2 (ja) * 2020-10-22 2025-11-20 日本メジフィジックス株式会社 放射性ジルコニウム錯体の製造方法
EP4326344A4 (en) * 2021-04-23 2025-05-07 Fusion Pharmaceuticals Inc. Methods for treatment of cancers
AU2022273867A1 (en) * 2021-05-13 2023-11-23 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
EP4355317A4 (en) * 2021-06-16 2025-04-30 Fusion Pharmaceuticals Inc. COMBINATION WITH A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX
EP4355377A4 (en) * 2021-06-16 2025-05-07 Fusion Pharmaceuticals Inc. COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
WO2022261770A1 (en) * 2021-06-16 2022-12-22 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
IL314533A (en) * 2022-01-28 2024-09-01 Fusion Pharmaceuticals Inc Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
EP4479040A1 (en) * 2022-02-18 2024-12-25 Full-Life Technologies HK Limited Compounds and radioligands for targeting neurotensin receptor and uses thereof
AU2023264077A1 (en) * 2022-05-03 2024-11-14 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications
US12091454B2 (en) 2022-12-28 2024-09-17 Development Center For Biotechnology Humanized anti-human neurotensin receptor 1 antibodies and their uses
US20250213735A1 (en) * 2023-12-28 2025-07-03 Radionetics Oncology, Inc. Neuropeptide y1 receptor (npy1r) targeted therapeutics and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
WO1995022341A1 (en) 1994-02-18 1995-08-24 Mallinckrodt Medical, Inc. Labelled peptide compounds
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
AU728712C (en) 1997-02-03 2001-07-19 Mallinckrodt, Inc. Method for the detection and localization of malignant human tumours
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
AU3485999A (en) 1998-04-10 1999-11-01 Mayo Foundation For Medical Education And Research Neo-tryptophan
EP1194444A2 (en) 1999-06-24 2002-04-10 BioSynthema Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
US20050112065A1 (en) * 2003-07-09 2005-05-26 Drummond Daryl C. Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
EP2114461A2 (en) * 2007-01-19 2009-11-11 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010079158A1 (en) * 2009-01-07 2010-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
WO2011006985A1 (en) 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
PT3712131T (pt) 2023-04-04
MX2015007193A (es) 2016-03-17
WO2014086499A1 (en) 2014-06-12
HK1210148A1 (en) 2016-04-15
FI3712131T3 (fi) 2023-03-28
HUE061839T2 (hu) 2023-08-28
DK2928870T3 (da) 2020-07-13
AU2013354422B2 (en) 2018-03-15
ZA201503446B (en) 2016-01-27
JP2019218375A (ja) 2019-12-26
JP6576828B2 (ja) 2019-09-18
US10961199B2 (en) 2021-03-30
CA2893605A1 (en) 2014-06-12
WO2014086499A8 (en) 2014-12-31
DK3712131T3 (da) 2023-03-20
JP7042776B2 (ja) 2022-03-28
IL239080B (en) 2019-06-30
US20150299133A1 (en) 2015-10-22
EP2928870A1 (en) 2015-10-14
CN104837819B9 (zh) 2019-07-09
BR112015012530B1 (pt) 2022-07-19
EP2928870B1 (en) 2020-04-08
US20260078095A1 (en) 2026-03-19
AU2013354422A1 (en) 2015-05-28
BR112015012530A2 (pt) 2017-09-12
SG10201704564QA (en) 2017-07-28
CN109320502A (zh) 2019-02-12
PT2928870T (pt) 2020-05-29
ES2795923T3 (es) 2020-11-25
CN104837819A (zh) 2015-08-12
JP2016501238A (ja) 2016-01-18
US20210087149A1 (en) 2021-03-25
IL239080A0 (en) 2015-07-30
EP3712131B1 (en) 2023-02-01
RU2015127086A (ru) 2017-01-11
ES2941629T3 (es) 2023-05-24
CN104837819B (zh) 2018-12-07
SG11201503880YA (en) 2015-06-29
RU2671970C2 (ru) 2018-11-08
KR102290803B1 (ko) 2021-08-18
HUE050388T2 (hu) 2020-11-30
CN109320502B (zh) 2022-06-07
PL3712131T3 (pl) 2023-05-02
EP3712131A1 (en) 2020-09-23
EP2740726A1 (en) 2014-06-11
CA2893605C (en) 2021-08-10
MX370354B (es) 2019-12-10
KR20150092300A (ko) 2015-08-12

Similar Documents

Publication Publication Date Title
NO2026005I1 (no) Dorocubicel
FIC20230009I1 (fi) Relatlimabi
NO2022024I1 (no) Roxadustat
PL2928870T3 (pl) Ligandy receptora neurotensyny
PT2878018T (pt) Resumo
PT2819623T (pt) Resumo
EP2902071A4 (en) INTERCONNECTS
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
DK2684610T4 (da) Bruser
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
PT2674413T (pt) Resumo
PT2831109T (pt) Resumo
PT2825212T (pt) Resumo
FR2998638B1 (fr) Raccord
DK2825157T3 (da) Aminosyrelipider
EP2871398A4 (en) INTERCONNECTS
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DE112012005566T8 (de) Seltenerdnanoverbundmagnet